Page last updated: 2024-10-23

benserazide and Drug Withdrawal Symptoms

benserazide has been researched along with Drug Withdrawal Symptoms in 7 studies

Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.
benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.

Research Excerpts

ExcerptRelevanceReference
"Levodopa treatment might change the dopaminergic and serotoninergic neuronal systems, but not the noradrenergic or adrenergic neuronal systems, in CNS of PD patients."1.29Monoamines and their metabolites in plasma and lumbar cerebrospinal fluid of Chinese patients with Parkinson's disease. ( Cheng, FC; Chia, LG; Kuo, JS, 1993)

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19903 (42.86)18.7374
1990's3 (42.86)18.2507
2000's1 (14.29)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Casseron, W1
Genton, P1
Bailey, R1
Crisp, E1
Jackson, DM1
Jenkins, O1
Kukuev, LA1
Sergutina, AV1
Gershteĭn, LM1
Olivé, JM1
Masana, L1
González, J1
Chia, LG1
Cheng, FC1
Kuo, JS1
Kuschinsky, K1
Herz, A1
Bläsig, J1
Papeschi, R1

Other Studies

7 other studies available for benserazide and Drug Withdrawal Symptoms

ArticleYear
DOPA-sensitive dystonia-plus syndrome.
    Developmental medicine and child neurology, 2005, Volume: 47, Issue:3

    Topics: Adolescent; Benserazide; Brain; Child; Child Behavior Disorders; Child, Preschool; Craniofacial Abno

2005
Chronic L-DOPA treatment of mice: a behavioural and biochemical study.
    Journal of neural transmission, 1981, Volume: 50, Issue:2-4

    Topics: Animals; Apomorphine; Benserazide; Body Temperature Regulation; Brain; Clonidine; Dihydroxyphenylala

1981
[Pathochemical changes in the motor structures of the brain under the influence of the administration of L-DOPA preparations and their withdrawal (experimental research)].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 1994, Volume: 94, Issue:5

    Topics: Animals; Benserazide; Brain; Brain Chemistry; Drug Combinations; Histocytochemistry; Levodopa; Rats;

1994
Meperidine and reversible parkinsonism.
    Movement disorders : official journal of the Movement Disorder Society, 1994, Volume: 9, Issue:1

    Topics: Adult; Benserazide; Drug Therapy, Combination; Humans; Levodopa; Male; Meperidine; Neurologic Examin

1994
Monoamines and their metabolites in plasma and lumbar cerebrospinal fluid of Chinese patients with Parkinson's disease.
    Journal of the neurological sciences, 1993, Volume: 116, Issue:2

    Topics: Aged; Benserazide; Biogenic Monoamines; China; Chromatography, High Pressure Liquid; Female; Humans;

1993
Does chronic morphine treatment induce a supersensitivity of dopamine receptors in rat brain?
    Psychopharmacologia, 1975, Jun-19, Volume: 42, Issue:3

    Topics: Animals; Apomorphine; Benserazide; Brain; Corpus Striatum; Dopamine; Homovanillic Acid; Humans; Levo

1975
Role of catecholaminergic mechanisms in the expression of the morphine abstinence syndrome in rats.
    Psychopharmacologia, 1974, Volume: 39, Issue:2

    Topics: Animals; Apomorphine; Behavior, Animal; Benserazide; Brain Chemistry; Catecholamines; Cocaine; Desip

1974